Neogen Corporation

Valuation Analysis

About the Company

Neogen Corporation en bref

Neogen Corporation (NEOG) is currently trading at 8,12 € with a market capitalization of 1,8 Md €. The 52-week range spans from 3,98 € to 9,96 €; the current price is 18.5% below the yearly high. Year-over-year revenue growth stands at -4.4%.

💰 Dividende

Neogen Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

3 analystes évaluent Neogen Corporation (NEOG) au consensus : Acheter. L'objectif de cours moyen est de 10,46 €, soit un potentiel de +28.89% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 9,59 € à 11,33 €.

Neogen Corporation : la thèse d'investissement en détail

Neogen Corporation (NEOG) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 28.89% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -4.4% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valorisation en contexte

With a PEG ratio of 0.66, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 32.76x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The analyst consensus price target implies 28.89% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to above-average price swings, elevated short interest (8%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Neogen Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.